These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7711465)

  • 1. Naloxone does not prevent apomorphine-induced emesis or hypotension in dogs.
    Montastruc JL; Lapeyre-Mestre M; Llau ME; Senard JM; Rascol O; Montastruc P
    Clin Auton Res; 1994 Dec; 4(6):303-5. PubMed ID: 7711465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apomorphine-induced emesis in the dog--routes of administration, efficacy and synergism by naloxone.
    Scherkl R; Hashem A; Frey HH
    J Vet Pharmacol Ther; 1990 Jun; 13(2):154-8. PubMed ID: 2384906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone or haloperidol but not yohimbine reverse apomorphine-induced respiratory depression.
    Montastruc JL; Rascol O; Montastruc P
    Clin Neuropharmacol; 1992 Oct; 15(5):404-7. PubMed ID: 1423340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereospecific antiarrhythmic effects of naloxone against myocardial ischaemia and reperfusion in the dog.
    Lee AY
    Br J Pharmacol; 1992 Dec; 107(4):1057-60. PubMed ID: 1467828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three preclinical models for nausea and vomiting assessment.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastric relaxation and vomiting by apomorphine, morphine and fentanyl in the conscious dog.
    Lefebvre RA; Willems JL; Bogaert MG
    Eur J Pharmacol; 1981 Jan; 69(2):139-45. PubMed ID: 7202514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the cardiovascular actions of apomorphine in dogs: central versus peripheral mechanisms and role of the adrenal medulla.
    Montastruc JL; Guiol C; Tran MA; Lhoste F; Montastruc P
    Arch Int Pharmacodyn Ther; 1985 Sep; 277(1):92-103. PubMed ID: 4062436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of naloxone to prevent the emetic activity of apomorphine in dogs.
    Keith JC; Wilson RC; Booth NH; Kemppainen RJ
    J Vet Pharmacol Ther; 1981 Dec; 4(4):315-6. PubMed ID: 7349348
    [No Abstract]   [Full Text] [Related]  

  • 9. Enkephalin receptors in the emetic chemoreceptor trigger zone of the dog.
    Bhargava KP; Dixit KS; Gupta YK
    Br J Pharmacol; 1981 Mar; 72(3):471-5. PubMed ID: 6266566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the relationship between clonidine hypotension and brain beta-endorphin in the spontaneously hypertensive rat: studies with alpha adrenergic and opiate blockers.
    Mastrianni JA; Ingenito AJ
    J Pharmacol Exp Ther; 1987 Jul; 242(1):378-87. PubMed ID: 3039113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil.
    Freye E; Neruda B; Smith OW
    Arzneimittelforschung; 1997 Jan; 47(1):6-9. PubMed ID: 9037435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental study of the hypotensive effect of apomorphine].
    Montastruc JL; Guiol C
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1176-80. PubMed ID: 6441536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of naloxone to reverse apomorphine effects in humans.
    Rowbotham MC; Joseph MS; Jones RT; Keil LC
    Psychoneuroendocrinology; 1983; 8(1):95-102. PubMed ID: 6308702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naloxone partly counteracts apomorphine side effects.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Clin Neuropharmacol; 1991 Oct; 14(5):442-9. PubMed ID: 1742754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of tolerance to apomorphine.
    Montastruc JL; Llau ME; Senard JM; Tran MA; Rascol O; Montastruc P
    Br J Pharmacol; 1996 Mar; 117(5):781-6. PubMed ID: 8851490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
    Eglen RM; Lee CH; Smith WL; Johnson LG; Clark R; Whiting RL; Hegde SS
    Br J Pharmacol; 1995 Feb; 114(4):860-6. PubMed ID: 7773547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the effects of naloxone hydrochloride and methiodide on endotoxic shock in the anesthetized rat].
    Rios L; Jacob J
    Arch Inst Pasteur Tunis; 1981; 58(3):313-27. PubMed ID: 7316611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine potentiates vagal bradycardia.
    Montastruc P; Damase-Michel C; Montastruc JL
    Eur J Pharmacol; 1989 Aug; 166(3):511-4. PubMed ID: 2680522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reversal of hemorrhagic hypotension by naloxone in conscious rabbits.
    Schadt JC; York DH
    Can J Physiol Pharmacol; 1981 Dec; 59(12):1208-13. PubMed ID: 7337874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of naloxone on pressor responses to angiotensin II in anaesthetized greyhounds.
    Wilkinson DL; Scroop GC
    Clin Exp Pharmacol Physiol; 1986 Mar; 13(3):179-86. PubMed ID: 3720019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.